entertainment
/
advertisements

Coca-Cola's AI-Generated 'Holidays Are Coming' Ad Sparks Debate

1 hour ago

Coca-Cola's AI-Generated 'Holidays Are Coming' Ad Sparks Debate
Generated image for illustrative purposes:

7 Highlights

  • Coca-Cola releases AI-driven 'Holidays Are Coming' ad in the UK.
  • The ad, inspired by the 1995 classic, uses AI to modernize nostalgia.
    • Santa is absent, possibly due to AI hurdles or creative choices.
    • Coca-Cola's Real Magic AI, with GPT-4 and Dall-E, powers the ad.
    • Javier Meza stresses updating the ad for today's audience.
    • Consumer feedback tested positive for the AI-created ad.
    • Classic truck in the ad distributes Coca-Cola Zero Sugar bottles.
0 Comments

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Related Articles

Elon Musk's DOGE Hiring Spree Faces Controversy Amid New Government Role
Generated image for illustrative purposes:

Elon Musk's DOGE Hiring Spree Faces Controversy Amid New Government Role

12 seconds ago

  • Musk and Ramaswamy lead a new department focused on government efficiency.
    • Trump enlists Musk to reduce $6.5 trillion federal spending through DOGE.
    • DOGE jobs demand high workload but do not offer payment.
    • Applicants need to subscribe to X for $84/year to apply for DOGE jobs.
    • DOGE seeks 'high-IQ small-government' followers for its mission.
    • Resumes are submitted via direct message on Musk's platform, X.
    • Dogecoin gains value following the announcement involving Musk.
0
Venezuela Holds Brazil to Historic Draw Amid Pitch Drama and Strategic Moves
Generated image for illustrative purposes:

Venezuela Holds Brazil to Historic Draw Amid Pitch Drama and Strategic Moves

27 seconds ago

  • Venezuela drew 1-1 with Brazil in a World Cup qualifier on Nov 14.
    • Telasco Segovia tied the game for Venezuela early in the second half.
    • Raphinha scored a rare free-kick goal for Brazil in the first half.
    • Vinicius Junior missed a crucial penalty for Brazil.
    • Sprinklers interrupted the match in stoppage time as Brazil attacked.
    • Venezuela's Alexander Gonzalez got a red card in the 89th minute.
    • Brazil is third in Conmebol, Venezuela is seventh in qualifiers.
0
Rightmove Rejects Rupert Murdoch's REA Group's Third Bid Valued at £6.1 Billion
Generated image for illustrative purposes:

Rightmove Rejects Rupert Murdoch's REA Group's Third Bid Valued at £6.1 Billion

4 minutes ago

  • Rightmove declined REA Group's £6.1 billion bid, considering it undervalued.
    • REA Group has until September 30 to submit a new offer for Rightmove.
    • Rightmove's board advises shareholders to reject takeover offers.
    • This is REA's third attempt; each bid has slightly increased.
    • REA's attempts are viewed as opportunistic by Rightmove.
    • Rightmove remains the top UK property portal despite competition.
    • REA Group is majorly owned by Murdoch's News Corp.
0
Coca-Cola Faces Backlash Over AI-Generated Christmas Ad: A Festive Traversal
Generated image for illustrative purposes:

Coca-Cola Faces Backlash Over AI-Generated Christmas Ad: A Festive Traversal

4 minutes ago

  • Coca-Cola is criticized for its AI-generated Christmas ad, seen as a 'creepy nightmare.'
    • The AI ad revisits the 1995 'Holidays Are Coming' campaign with modern tech elements.
    • Viewers say the AI ad lacks emotion and the warmth of human creativity.
    • Pratik Thakar supports AI, citing its cost-effectiveness and versatility.
    • In contrast, Jason Zada highlights the need for genuine human warmth in ads.
    • The ad's backlash raises discussions on AI's role and the future of human creativity.
    • Coca-Cola argues AI ads save time and money, merging tradition with new tech.
0
EU Approves New Alzheimer's Drug After Initial Resistance
Generated image for illustrative purposes:

EU Approves New Alzheimer's Drug After Initial Resistance

4 minutes ago

  • EU approves Alzheimer's drug Leqembi after initial rejection.
    • Lecanemab slows cognitive decline by targeting amyloid plaques.
    • EMA resolved risk concerns with Leqembi's careful monitoring.
    • Leqembi is given biweekly via intravenous drip in specific cases.
    • Restrictions apply to ApoE4 gene carriers using Leqembi.
    • UK NHS excludes Leqembi over cost issues despite US approval.
    • Alzheimer's impacts 7.8M people in the EU; monitoring is vital.
0

Log in to continue reading

Unlimited Access
Personalized Feed
Full Experience

By continuing, you agree to the Privacy Policy. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.